USHR Urges Congressional Action In Response To FDA’S Misguided Promotion Of Incomplete CBD Safety Data

General Counsel Jonathan Miller Raises Concerns Regarding FDA’s Stance on CBD Regulation WASHINGTON D.C. — On the heels of last week’s U.S. Food and Drug Administration (FDA) webinar for hemp industry stakeholders, “A New Way Forward for Cannabidiol and Other Hemp Products,” U.S. Hemp Roundtable General Counsel, Jonathan Miller, wrote key congressional leaders alerting them […]